|
PT1234031T
(pt)
|
1999-11-30 |
2017-06-26 |
Mayo Foundation |
B7-h1, uma nova molécula imunoregulatória
|
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
|
SI1781682T1
(sl)
|
2004-06-24 |
2013-05-31 |
Mayo Foundation For Medical Education And Research |
B7-H5, so-stimulatorni polipeptid
|
|
PT3428191T
(pt)
|
2004-10-06 |
2024-12-30 |
Mayo Found Medical Education & Res |
B7-h1 e tratamento do carcinona de células renais
|
|
US8231872B2
(en)
|
2005-04-25 |
2012-07-31 |
The Trustees Of Dartmouth College |
Regulatory T cell mediator proteins and uses thereof
|
|
EP2514762B1
(en)
|
2007-07-13 |
2015-04-08 |
The Johns Hopkins University |
B7-DC variants
|
|
ES2741730T3
(es)
|
2008-05-19 |
2020-02-12 |
Advaxis Inc |
Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
|
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
|
CA2735006A1
(en)
*
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Pd-1 antagonists and methods of use thereof
|
|
EP2927240A1
(en)
|
2008-08-25 |
2015-10-07 |
Amplimmune, Inc. |
Compositions of pd-1 antagonists and methods of use
|
|
WO2010077634A1
(en)
|
2008-12-09 |
2010-07-08 |
Genentech, Inc. |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
JP5539411B2
(ja)
*
|
2009-03-04 |
2014-07-02 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
血管新生因子を含む組成物およびその使用方法
|
|
AU2010229994B2
(en)
|
2009-03-25 |
2016-08-18 |
Genentech, Inc. |
Anti-FGFR3 antibodies and methods using same
|
|
KR101495951B1
(ko)
|
2009-03-30 |
2015-02-25 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
리포솜 조성물
|
|
CN107252489A
(zh)
|
2009-04-13 |
2017-10-17 |
法国健康和医学研究院 |
Hpv颗粒及其用途
|
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
|
US20130017199A1
(en)
*
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
|
CA2794483C
(en)
*
|
2010-03-26 |
2020-07-07 |
Trustees Of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
HUE058787T2
(hu)
*
|
2010-05-05 |
2022-09-28 |
Univ New York |
Staphylococcus aureus leukocidinek, terápiás készítmények és azok felhasználása
|
|
WO2012138377A2
(en)
|
2010-10-01 |
2012-10-11 |
Trustees Of The University Of Pennsylvania |
The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
|
US9029315B2
(en)
|
2010-11-11 |
2015-05-12 |
The University Of Hong Kong |
Soluble PD-1 variants, fusion constructs, and uses thereof
|
|
US9511151B2
(en)
|
2010-11-12 |
2016-12-06 |
Uti Limited Partnership |
Compositions and methods for the prevention and treatment of cancer
|
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
|
WO2012125551A1
(en)
|
2011-03-11 |
2012-09-20 |
Advaxis |
Listeria-based adjuvants
|
|
US9675561B2
(en)
|
2011-04-28 |
2017-06-13 |
President And Fellows Of Harvard College |
Injectable cryogel vaccine devices and methods of use thereof
|
|
CA2840409A1
(en)
|
2011-06-28 |
2013-01-03 |
Whitehead Institute For Biomedical Research |
Using sortases to install click chemistry handles for protein ligation
|
|
US9416132B2
(en)
|
2011-07-21 |
2016-08-16 |
Tolero Pharmaceuticals, Inc. |
Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
|
|
AR087405A1
(es)
|
2011-08-01 |
2014-03-19 |
Genentech Inc |
Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
|
|
BR112014009526B8
(pt)
*
|
2011-10-17 |
2023-01-17 |
Herlev Hospital |
Composição de vacina compreendendo pd-l1, kit de partes compreendendo tal composição e uso dos mesmos para tratar ou prevenir câncer
|
|
EP2825195A4
(en)
|
2012-03-12 |
2015-10-07 |
Advaxis Inc |
INHIBITION OF SUPPRESSOR CELL FUNCTION AFTER TREATMENT WITH A LISTERIAL VACCINE
|
|
US10988516B2
(en)
|
2012-03-26 |
2021-04-27 |
Uti Limited Partnership |
Methods and compositions for treating inflammation
|
|
EP2855528B1
(en)
|
2012-05-31 |
2019-06-19 |
Genentech, Inc. |
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
|
|
TWI677507B
(zh)
*
|
2012-06-22 |
2019-11-21 |
達特茅斯學院基金會 |
新穎之ｖｉｓｔａ－ｉｇ構築體及ｖｉｓｔａ－ｉｇ用於治療自體免疫、過敏及發炎病症之用途
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
EP2892558B1
(en)
|
2012-09-07 |
2019-04-10 |
The Trustees Of Dartmouth College |
Vista modulators for diagnosis and treatment of cancer
|
|
US9603948B2
(en)
|
2012-10-11 |
2017-03-28 |
Uti Limited Partnership |
Methods and compositions for treating multiple sclerosis and related disorders
|
|
WO2014059403A1
(en)
*
|
2012-10-12 |
2014-04-17 |
University Of Miami |
Chimeric proteins, compositions and methods for restoring cholinesterase function at neuromuscular synapses
|
|
EP4223770A3
(en)
|
2012-11-05 |
2023-10-18 |
Foundation Medicine, Inc. |
Novel fusion molecules and uses thereof
|
|
HK1214830A1
(zh)
|
2012-11-05 |
2016-08-05 |
Foundation Medicine, Inc. |
新型ntrk1融合分子及其应用
|
|
KR101968637B1
(ko)
|
2012-12-07 |
2019-04-12 |
삼성전자주식회사 |
유연성 반도체소자 및 그 제조방법
|
|
EP3939614A1
(en)
|
2013-01-18 |
2022-01-19 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
CN103965363B
(zh)
*
|
2013-02-06 |
2021-01-15 |
上海白泽生物科技有限公司 |
与pd-1和vegf高效结合的融合蛋白、其编码序列及用途
|
|
WO2014124217A1
(en)
*
|
2013-02-07 |
2014-08-14 |
Albert Einstein College Of Medicine Of Yeshiva University |
A selective high-affinity immune stimulatory reagent and uses thereof
|
|
SG11201505896YA
(en)
|
2013-02-20 |
2015-09-29 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
EP3744736A1
(en)
|
2013-02-20 |
2020-12-02 |
Novartis AG |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
CA2909160C
(en)
|
2013-04-09 |
2021-05-25 |
Lixte Biotechnology, Inc. |
Formulations of oxabicycloheptanes and oxabicycloheptenes
|
|
JP6433085B2
(ja)
|
2013-04-09 |
2018-12-05 |
ボストン バイオメディカル， インコーポレイテッド |
がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
|
|
EP3693398A1
(en)
|
2013-05-10 |
2020-08-12 |
Whitehead Institute for Biomedical Research |
In vitro production of red blood cells with sortaggable proteins
|
|
US10260038B2
(en)
|
2013-05-10 |
2019-04-16 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
|
DK3021869T3
(da)
|
2013-07-16 |
2020-09-21 |
Hoffmann La Roche |
Fremgangsmåder til behandling af cancer ved anvendelse af PD-1-aksebindende antagonister og TIGIT-hæmmere
|
|
EP3030262B1
(en)
|
2013-08-08 |
2019-10-09 |
Cytune Pharma |
Combined pharmaceutical composition
|
|
US11273204B2
(en)
|
2013-08-08 |
2022-03-15 |
Cytune Pharma |
IL-15 and IL-15RAPLHA sushi domain based immunocytokines
|
|
KR102232153B1
(ko)
|
2013-08-20 |
2021-03-24 |
머크 샤프 앤드 돔 코포레이션 |
Pd-1 길항제와 디나시클립의 조합을 사용한 암의 치료
|
|
ES2747762T3
(es)
|
2013-08-21 |
2020-03-11 |
Curevac Ag |
Vacuna contra el virus respiratorio sincitial (RSV)
|
|
KR102186363B1
(ko)
|
2013-09-06 |
2020-12-04 |
삼성전자주식회사 |
c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물
|
|
ES2792183T3
(es)
|
2013-09-13 |
2020-11-10 |
Beigene Switzerland Gmbh |
Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
|
|
MX385842B
(es)
|
2013-09-18 |
2025-03-18 |
Aura Biosciences Inc |
Conjugados de partículas de tipo virus y uso de las mismas.
|
|
EP3757130A1
(en)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
US10259875B2
(en)
|
2013-10-01 |
2019-04-16 |
Mayo Foundation For Medical Education And Research |
Methods for treating cancer in patients with elevated levels of BIM
|
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
|
SG10201912301XA
(en)
|
2013-11-04 |
2020-02-27 |
Uti Lp |
Methods and compositions for sustained immunotherapy
|
|
US10556024B2
(en)
|
2013-11-13 |
2020-02-11 |
Whitehead Institute For Biomedical Research |
18F labeling of proteins using sortases
|
|
JP2016537345A
(ja)
|
2013-11-13 |
2016-12-01 |
ノバルティス アーゲー |
免疫応答を増強するためのｍＴＯＲ阻害剤
|
|
CA2931322A1
(en)
|
2013-11-22 |
2015-05-28 |
Dnatrix, Inc. |
Adenovirus expressing immune cell stimulatory receptor agonist(s)
|
|
EP3074035B1
(en)
|
2013-11-25 |
2020-05-13 |
FameWave Ltd. |
Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
|
|
US10241115B2
(en)
|
2013-12-10 |
2019-03-26 |
Merck Sharp & Dohme Corp. |
Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
|
|
PE20160953A1
(es)
|
2013-12-12 |
2016-09-26 |
Shanghai hengrui pharmaceutical co ltd |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
|
|
MX2016007965A
(es)
|
2013-12-17 |
2016-10-28 |
Genentech Inc |
Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
|
|
KR20160089532A
(ko)
|
2013-12-17 |
2016-07-27 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 항-cd20 항체를 사용하여 암을 치료하는 방법
|
|
KR102630750B1
(ko)
|
2013-12-17 |
2024-01-30 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
|
|
WO2015094992A1
(en)
|
2013-12-17 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
|
|
CA3225453A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
US20170044268A1
(en)
*
|
2013-12-23 |
2017-02-16 |
OncoMed Pharmaceuticals |
Immunotherapy with Binding Agents
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
CN119775416A
(zh)
|
2013-12-24 |
2025-04-08 |
杨森制药公司 |
抗vista抗体及片段
|
|
EP4070818A3
(en)
*
|
2014-01-06 |
2023-01-11 |
The Trustees of the University of Pennsylvania |
Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
TW201613635A
(en)
|
2014-02-04 |
2016-04-16 |
Pfizer |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
|
AU2015214390B2
(en)
|
2014-02-04 |
2020-05-07 |
Merck Sharp & Dohme LLC. |
Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
|
|
CA2938566A1
(en)
|
2014-02-04 |
2015-08-13 |
Incyte Corporation |
Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
|
|
ME03558B
(me)
|
2014-03-14 |
2020-07-20 |
Novartis Ag |
Molekuli anti-lag-3 antiтela i njihove upotrebe
|
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
HRP20190501T1
(hr)
|
2014-03-24 |
2019-05-03 |
Novartis Ag |
Monobaktam organski spojevi za liječenje bakterijskih infekcija
|
|
EP3632934A1
(en)
|
2014-03-31 |
2020-04-08 |
F. Hoffmann-La Roche AG |
Anti-ox40 antibodies and methods of use
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
FI3888674T3
(fi)
|
2014-04-07 |
2024-07-02 |
Novartis Ag |
Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria
|
|
US10682400B2
(en)
*
|
2014-04-30 |
2020-06-16 |
President And Fellows Of Harvard College |
Combination vaccine devices and methods of killing cancer cells
|
|
CN103965364B
(zh)
*
|
2014-05-19 |
2016-06-08 |
亚飞（上海）生物医药科技有限公司 |
一种人源pdl2hsa系列融合蛋白及其制备与应用
|
|
WO2015179654A1
(en)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti b7-h1 antibodies
|
|
AU2015265607A1
(en)
|
2014-05-28 |
2016-11-17 |
Idenix Pharmaceuticals Llc |
Nucleoside derivatives for the treatment of cancer
|
|
JP6997619B2
(ja)
|
2014-06-11 |
2022-01-17 |
キャシー・エイ・グリーン |
液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
|
|
US10449227B2
(en)
*
|
2014-06-27 |
2019-10-22 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Conjugates for immunotherapy
|
|
CN106604742B
(zh)
|
2014-07-03 |
2019-01-11 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
|
EP3309174B1
(en)
|
2014-07-11 |
2022-05-11 |
Ventana Medical Systems, Inc. |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
|
SG11201700281SA
(en)
*
|
2014-07-14 |
2017-02-27 |
Queensland Inst Med Res |
Galectin immunotherapy
|
|
AR101210A1
(es)
|
2014-07-15 |
2016-11-30 |
Genentech Inc |
Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek
|
|
MX2017000857A
(es)
|
2014-07-18 |
2017-10-11 |
Advaxis Inc |
Combinación de un antagonista de la proteina de muerte programada (pd-1) y una vacuna basada en listeria para tratar el cáncer de próstata.
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
BR112017001242A2
(pt)
|
2014-07-21 |
2017-12-05 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico a cd33
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
SG11201700496WA
(en)
|
2014-07-22 |
2017-02-27 |
Cb Therapeutics Inc |
Anti-pd-1 antibodies
|
|
US10517875B2
(en)
|
2014-07-23 |
2019-12-31 |
Mayo Foundation for Medical Engineering and Research |
Targeting DNA-PKcs and B7-H1 to treat cancer
|
|
US20170209492A1
(en)
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
SG10201901057UA
(en)
|
2014-08-05 |
2019-03-28 |
Cb Therapeutics Inc |
Anti-pd-l1 antibodies
|
|
JP2017523213A
(ja)
|
2014-08-06 |
2017-08-17 |
ノバルティス アーゲー |
抗菌薬としてのキノロン誘導体
|
|
CN106687124B
(zh)
|
2014-08-07 |
2022-03-15 |
冈村春树 |
并用il-18与分子靶向抗体的癌治疗药
|
|
EP3177640B1
(en)
|
2014-08-08 |
2020-05-06 |
The Board of Trustees of the Leland Stanford Junior University |
High affinity pd-1 agents and methods of use
|
|
JP6919118B2
(ja)
|
2014-08-14 |
2021-08-18 |
ノバルティス アーゲー |
ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
|
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
US10695426B2
(en)
|
2014-08-25 |
2020-06-30 |
Pfizer Inc. |
Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
|
|
HRP20190881T1
(hr)
|
2014-08-28 |
2019-07-12 |
Halozyme, Inc. |
Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke
|
|
MA40132B1
(fr)
|
2014-09-11 |
2019-04-30 |
Bristol Myers Squibb Co |
Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
|
EA201790737A1
(ru)
|
2014-10-03 |
2017-08-31 |
Новартис Аг |
Комбинированная терапия
|
|
US10053683B2
(en)
|
2014-10-03 |
2018-08-21 |
Whitehead Institute For Biomedical Research |
Intercellular labeling of ligand-receptor interactions
|
|
CN106973568B
(zh)
|
2014-10-08 |
2021-07-23 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
CN107428825A
(zh)
*
|
2014-10-10 |
2017-12-01 |
创祐生技股份有限公司 |
治疗及/或预防肿瘤生长、侵袭及/或转移的方法
|
|
EP3207130B1
(en)
|
2014-10-14 |
2019-08-07 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
|
MX389663B
(es)
|
2014-10-14 |
2025-03-20 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
|
|
MX382902B
(es)
*
|
2014-10-31 |
2025-03-13 |
Oncomed Pharm Inc |
Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
|
|
MX2017005750A
(es)
|
2014-11-03 |
2017-12-15 |
Genentech Inc |
Ensayos para detectar subgrupos inmunes de células t y sus métodos de uso.
|
|
CA2966507A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
|
PE20170912A1
(es)
|
2014-11-14 |
2017-07-12 |
Novartis Ag |
Conjugados de anticuerpo-farmaco
|
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
|
LT3789402T
(lt)
|
2014-11-20 |
2022-09-26 |
F. Hoffmann-La Roche Ag |
Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
|
|
WO2016086200A1
(en)
|
2014-11-27 |
2016-06-02 |
Genentech, Inc. |
4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
JP2017537929A
(ja)
|
2014-12-05 |
2017-12-21 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１軸アンタゴニスト及びｈｐｋ１アンタゴニストを用いたがん治療のための方法及び組成物
|
|
AU2015357463B2
(en)
|
2014-12-05 |
2021-10-07 |
Immunext, Inc. |
Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
|
|
WO2016089833A1
(en)
|
2014-12-05 |
2016-06-09 |
Merck Sharp & Dohme Corp. |
Novel tricyclic compounds as inhibitors of mutant idh enzymes
|
|
EP3226689B1
(en)
|
2014-12-05 |
2020-01-15 |
Merck Sharp & Dohme Corp. |
Novel tricyclic compounds as inhibitors of mutant idh enzymes
|
|
EP3226688B1
(en)
|
2014-12-05 |
2020-07-01 |
Merck Sharp & Dohme Corp. |
Tricyclic compounds as inhibitors of mutant idh enzymes
|
|
WO2016094273A1
(en)
|
2014-12-08 |
2016-06-16 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
|
|
EP3230498B1
(en)
|
2014-12-09 |
2023-01-18 |
Merck Sharp & Dohme LLC |
System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
|
|
EA032138B1
(ru)
|
2014-12-16 |
2019-04-30 |
Новартис Аг |
СОЕДИНЕНИЯ ИЗОКСАЗОЛГИДРОКСАМИНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LpxC
|
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
EP3250250A4
(en)
|
2015-01-30 |
2019-05-22 |
President and Fellows of Harvard College |
PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
CN112263677A
(zh)
|
2015-02-26 |
2021-01-26 |
默克专利股份公司 |
用于治疗癌症的pd-1/pd-l1抑制剂
|
|
AU2016226157B2
(en)
|
2015-03-04 |
2022-01-27 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and eribulin for treating cancer
|
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
|
US10449211B2
(en)
|
2015-03-10 |
2019-10-22 |
Aduro Biotech, Inc. |
Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
|
|
EP3067062A1
(en)
|
2015-03-13 |
2016-09-14 |
Ipsen Pharma S.A.S. |
Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
|
|
WO2016147182A1
(en)
*
|
2015-03-16 |
2016-09-22 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Isolated peptides derived from the b7 ligand dimer interface and uses thereof
|
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
EP3273944B1
(en)
*
|
2015-03-25 |
2024-11-20 |
The Regents of The University of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
US11933786B2
(en)
|
2015-03-30 |
2024-03-19 |
Stcube, Inc. |
Antibodies specific to glycosylated PD-L1 and methods of use thereof
|
|
AU2016246695A1
(en)
|
2015-04-07 |
2017-10-26 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
|
ES2876974T3
(es)
|
2015-04-07 |
2021-11-15 |
Novartis Ag |
Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
|
|
EP3283508B1
(en)
|
2015-04-17 |
2021-03-17 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins with tunable affinities
|
|
CN108473957B
(zh)
|
2015-04-17 |
2024-07-16 |
诺华股份有限公司 |
改善嵌合抗原受体表达细胞的功效和扩增的方法
|
|
WO2016168133A1
(en)
|
2015-04-17 |
2016-10-20 |
Merck Sharp & Dohme Corp. |
Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
DE112016002056T5
(de)
|
2015-05-06 |
2018-02-08 |
Snipr Technologies Limited |
Verändern mikrobieller Populationen und Modifizieren von Mikrobiomen
|
|
US12011480B2
(en)
|
2015-05-06 |
2024-06-18 |
Uti Limited Partnership |
Nanoparticle compositions for sustained therapy
|
|
WO2016183326A1
(en)
|
2015-05-12 |
2016-11-17 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
JP6510075B2
(ja)
|
2015-05-18 |
2019-05-08 |
トレロ ファーマシューティカルズ， インコーポレイテッド |
バイオアベイラビリティが高いアルボシジブプロドラッグ
|
|
CN111234027A
(zh)
|
2015-05-21 |
2020-06-05 |
哈普恩治疗公司 |
三特异性结合蛋白质及使用方法
|
|
CN108368147A
(zh)
|
2015-05-27 |
2018-08-03 |
南方研究院 |
用于治疗癌症的核苷酸
|
|
MX2017015308A
(es)
|
2015-05-29 |
2018-07-06 |
Merck Sharp & Dohme |
Combinacion de un antagonista de pd-1 y un oligonucleotido tipo cpg-c para tratar cancer.
|
|
IL294138A
(en)
|
2015-05-29 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
JP2018517708A
(ja)
|
2015-06-05 |
2018-07-05 |
ニューヨーク・ユニバーシティ |
抗ブドウ球菌生物学的薬剤のための組成物及び方法
|
|
KR20180011839A
(ko)
|
2015-06-08 |
2018-02-02 |
제넨테크, 인크. |
항-ox40 항체를 이용한 암의 치료 방법
|
|
MX2017015811A
(es)
*
|
2015-06-12 |
2018-04-10 |
Squibb Bristol Myers Co |
Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
|
|
MY193229A
(en)
|
2015-06-16 |
2022-09-26 |
Merck Patent GmbH |
Pd-l1 antagonist combination treatments
|
|
EP3310813A1
(en)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Antibody drug conjugates
|
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
|
EP3722314A1
(en)
|
2015-06-24 |
2020-10-14 |
Janssen Pharmaceutica NV |
Anti-vista antibodies and fragments
|
|
CA2990107A1
(en)
|
2015-06-24 |
2016-12-29 |
Immodulon Therapeutics Limited |
A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
|
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
CA2986705A1
(en)
|
2015-07-16 |
2017-01-19 |
Biokine Therapeutics Ltd. |
A cxcr4 inhibitor and a pdi antagonist for use in treating cancer
|
|
JP7146632B2
(ja)
|
2015-07-21 |
2022-10-04 |
ノバルティス アーゲー |
免疫細胞の有効性および増大を改善する方法
|
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
BR112018001640A2
(pt)
|
2015-07-29 |
2018-09-18 |
Novartis Ag |
combinação de antagonista da pd-1 com um inibidor de egfr
|
|
JP6840127B2
(ja)
|
2015-07-29 |
2021-03-10 |
ノバルティス アーゲー |
がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用
|
|
EA034786B1
(ru)
|
2015-08-13 |
2020-03-20 |
Мерк Шарп И Доум Корп. |
Циклические динуклеотидные соединения в качестве агонистов sting
|
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
|
KR20180043835A
(ko)
|
2015-09-03 |
2018-04-30 |
에일러론 테라퓨틱스 인코포레이티드 |
펩티도미메틱 매크로사이클 및 이의 용도
|
|
CN108349985A
(zh)
|
2015-09-14 |
2018-07-31 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
|
CA3000386A1
(en)
|
2015-09-30 |
2017-04-06 |
Merck Patent Gmbh |
Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
|
|
US12048753B2
(en)
|
2015-10-01 |
2024-07-30 |
Whitehead Institute For Biomedical Research |
Labeling of antibodies
|
|
PE20180773A1
(es)
|
2015-10-02 |
2018-05-07 |
Hoffmann La Roche |
Anticuerpos biespecificos para pd1 y tim3
|
|
CA2997799A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-pd1 antibodies and methods of use
|
|
CN106565836B
(zh)
*
|
2015-10-10 |
2020-08-18 |
中国科学院广州生物医药与健康研究院 |
高亲和力的可溶性pdl-1分子
|
|
US11207393B2
(en)
|
2015-10-16 |
2021-12-28 |
President And Fellows Of Harvard College |
Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
|
|
JP7088835B2
(ja)
|
2015-10-16 |
2022-06-21 |
カンザス ステイト ユニバーシティ リサーチ ファウンデーション |
ブタサーコウイルス３型免疫原性組成物、その製造方法、およびその使用方法
|
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
MX2018005348A
(es)
|
2015-10-30 |
2018-08-14 |
Aleta Biotherapeutics Inc |
Composiciones y metodos para transduccion de tumores.
|
|
AU2016343722A1
(en)
*
|
2015-10-30 |
2018-05-24 |
Aleta Biotherapeutics, Inc. |
Targeted cancer therapy
|
|
CA3002674A1
(en)
|
2015-10-30 |
2017-05-04 |
Aleta Biotherapeutics Inc. |
Compositions and methods for treatment of cancer
|
|
US10875923B2
(en)
|
2015-10-30 |
2020-12-29 |
Mayo Foundation For Medical Education And Research |
Antibodies to B7-H1
|
|
WO2017079202A1
(en)
|
2015-11-02 |
2017-05-11 |
Board Of Regents, The University Of Texas System |
Methods of cd40 activation and immune checkpoint blockade
|
|
MA43163A
(fr)
|
2015-11-02 |
2018-09-12 |
Five Prime Therapeutics Inc |
Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer
|
|
WO2017077382A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
|
CN108884159A
(zh)
|
2015-11-07 |
2018-11-23 |
茂体外尔公司 |
用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物
|
|
SG10201911035QA
(en)
|
2015-11-18 |
2020-01-30 |
Merck Sharp & Dohme |
Pd1 and/or lag3 binders
|
|
JP6952691B2
(ja)
|
2015-11-19 |
2021-10-20 |
ジェネンテック， インコーポレイテッド |
Ｂ−ｒａｆ阻害剤及び免疫チェックポイント阻害剤を使用してがんを治療する方法
|
|
EP3383412A4
(en)
|
2015-12-02 |
2019-06-05 |
Stcube, Inc. |
SPECIFIC ANTIBODIES TO GLYCOSED PD-1 AND METHOD OF USE THEREOF
|
|
RU2020113165A
(ru)
|
2015-12-03 |
2020-06-09 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Циклические пуриновые динуклеотиды в качестве модуляторов sting
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
IL257696B2
(en)
|
2015-12-09 |
2024-11-01 |
Hoffmann La Roche |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
US10538497B2
(en)
|
2015-12-15 |
2020-01-21 |
Merck Sharp & Dohme Corp. |
Compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
EP3389712B1
(en)
|
2015-12-17 |
2024-04-10 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
UY37030A
(es)
|
2015-12-18 |
2017-07-31 |
Novartis Ag |
Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
|
|
MA44140A
(fr)
|
2015-12-22 |
2021-05-19 |
Dana Farber Cancer Inst Inc |
Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
|
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
|
BR112018014150A2
(en)
|
2016-01-11 |
2018-12-11 |
Novartis Ag |
immunostimulating humanized monoclonal antibodies to human interleukin-2, and fusion proteins thereof
|
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
|
CN116769054A
(zh)
|
2016-02-05 |
2023-09-19 |
奥里尼斯生物科学私人有限公司 |
双特异性信号传导剂及其用途
|
|
EP3411475B1
(en)
|
2016-02-06 |
2025-08-27 |
President and Fellows of Harvard College |
Recapitulating the hematopoietic niche to reconstitute immunity
|
|
MX2018009800A
(es)
|
2016-02-12 |
2018-11-09 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
|
|
SG11201805941WA
(en)
|
2016-02-17 |
2018-09-27 |
Novartis Ag |
Tgfbeta 2 antibodies
|
|
ES2897913T3
(es)
|
2016-02-19 |
2022-03-03 |
Novartis Ag |
Compuestos de piridona tetracíclicos como antivirales
|
|
CN109196121B
(zh)
|
2016-02-29 |
2022-01-04 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
CA3016287A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
|
CN109153719B
(zh)
|
2016-03-15 |
2022-12-30 |
中外制药株式会社 |
使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
|
|
KR20190080825A
(ko)
|
2016-03-21 |
2019-07-08 |
다나-파버 캔서 인스티튜트 인크. |
T-세포 기능소실 상태-특이적 유전자 발현 조절인자 및 그 용도
|
|
TW201735949A
(zh)
|
2016-03-24 |
2017-10-16 |
千禧製藥公司 |
治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
|
|
FI3433257T3
(fi)
|
2016-03-24 |
2024-01-08 |
Novartis Ag |
Alkynyylinukleosidianalogeja ihmisen rinoviruksen estäjinä
|
|
JP7069032B2
(ja)
|
2016-03-24 |
2022-05-17 |
ミレニアム ファーマシューティカルズ， インコーポレイテッド |
がん免疫治療における胃腸の免疫関連有害事象の治療方法
|
|
US11046782B2
(en)
|
2016-03-30 |
2021-06-29 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
|
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
CN113549110B
(zh)
|
2016-04-07 |
2024-08-16 |
葛兰素史密斯克莱知识产权发展有限公司 |
用作蛋白质调节剂的杂环酰胺
|
|
JP2019510802A
(ja)
|
2016-04-07 |
2019-04-18 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
タンパク質調節物質として有用な複素環アミド
|
|
CA3020830A1
(en)
|
2016-04-13 |
2017-10-19 |
Vivia Biotech, S.L |
Ex vivo bite.rtm. activated t cells
|
|
US11414497B2
(en)
|
2016-04-13 |
2022-08-16 |
Orimabs Ltd. |
Anti-PSMA antibodies and use thereof
|
|
KR20190003958A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암의 치료 및 모니터링 방법
|
|
CN109154027A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
|
EP3448412A4
(en)
|
2016-04-15 |
2020-03-25 |
Immunext Inc. |
ANTI-HUMAN-VISTA ANTIBODIES AND USE THEREOF
|
|
EP3443000B1
(en)
|
2016-04-15 |
2025-11-12 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
KR102824067B1
(ko)
|
2016-04-15 |
2025-06-23 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Icos 리간드 변이체 면역조절 단백질 및 그의 용도
|
|
CN105906715A
(zh)
*
|
2016-04-26 |
2016-08-31 |
中国人民解放军第四军医大学 |
PDL2-IgGFc融合蛋白抑制重症疟疾发病的应用
|
|
EP3449921B1
(en)
|
2016-04-28 |
2023-05-31 |
Eisai R&D Management Co., Ltd. |
Eribulin for inhibiting tumor growth
|
|
CA3022377A1
(en)
|
2016-04-29 |
2017-11-02 |
Board Of Regents, The University Of Texas System |
Targeted measure of transcriptional activity related to hormone receptors
|
|
WO2017192874A1
(en)
|
2016-05-04 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Albumin-binding immunomodulatory compositions and methods of use thereof
|
|
CA3023157A1
(en)
|
2016-05-05 |
2017-11-09 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
|
TWI794171B
(zh)
|
2016-05-11 |
2023-03-01 |
美商滬亞生物國際有限公司 |
Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
|
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
|
EP3454887B1
(en)
|
2016-05-13 |
2021-01-20 |
Orionis Biosciences BV |
Targeted mutant interferon-beta and uses thereof
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
CN109563141A
(zh)
|
2016-05-13 |
2019-04-02 |
奥里尼斯生物科学公司 |
对非细胞结构的治疗性靶向
|
|
MX2018014028A
(es)
|
2016-05-19 |
2019-04-04 |
Squibb Bristol Myers Co |
Inmunomoduladores de produccion de imagenes de tomografia por emision de positrones (pet).
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
JP7014736B2
(ja)
|
2016-05-24 |
2022-02-01 |
ジェネンテック， インコーポレイテッド |
がんの処置のためのピラゾロピリジン誘導体
|
|
CN115028617A
(zh)
|
2016-05-24 |
2022-09-09 |
基因泰克公司 |
Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
CN109563071B
(zh)
|
2016-06-08 |
2021-08-03 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为atf4途径抑制剂的化学化合物
|
|
RU2018146946A
(ru)
|
2016-06-08 |
2020-07-10 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Химические соединения
|
|
CA3029813A1
(en)
|
2016-06-13 |
2017-12-21 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
|
CA3026356A1
(en)
|
2016-06-14 |
2017-12-21 |
Novartis Ag |
Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
|
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
|
CN109641936B
(zh)
|
2016-06-21 |
2023-11-28 |
Io生物技术公司 |
用于癌症疫苗中的pdl1肽
|
|
CN106084042B
(zh)
*
|
2016-06-24 |
2020-01-14 |
安徽未名细胞治疗有限公司 |
一种全人源抗MAGEA1的全分子IgG抗体及其应用
|
|
CN109475536B
(zh)
|
2016-07-05 |
2022-05-27 |
百济神州有限公司 |
用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
|
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
CN115537372A
(zh)
|
2016-07-13 |
2022-12-30 |
哈佛学院院长等 |
抗原呈递细胞模拟支架及其制备和使用方法
|
|
US11365252B2
(en)
|
2016-07-20 |
2022-06-21 |
University Of Utah Research Foundation |
CD229 CAR T cells and methods of use thereof
|
|
JP2019521166A
(ja)
|
2016-07-20 |
2019-07-25 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
Ｐｅｒｋ阻害剤としてのイソキノリン誘導体
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
JP2019527236A
(ja)
|
2016-08-01 |
2019-09-26 |
モレキュラー テンプレーツ，インコーポレイティド |
癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
|
|
EP3493842A4
(en)
|
2016-08-02 |
2020-07-29 |
President and Fellows of Harvard College |
BIOMATERIALS TO MODULATE IMMUNE RESPONSES
|
|
CA3032826A1
(en)
*
|
2016-08-03 |
2018-02-08 |
Nextcure, Inc. |
Compositions and methods for modulating lair signal transduction
|
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
EP3497129A1
(en)
|
2016-08-08 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
|
CA3033105A1
(en)
*
|
2016-08-11 |
2018-02-15 |
The Council Of The Queensland Institute Of Medical Research |
Immune-modulating compounds
|
|
WO2018031865A1
(en)
|
2016-08-12 |
2018-02-15 |
Genentech, Inc. |
Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
|
|
PT3500299T
(pt)
|
2016-08-19 |
2024-02-21 |
Beigene Switzerland Gmbh |
Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
|
|
US11096924B2
(en)
|
2016-09-07 |
2021-08-24 |
Trustees Of Tufts College |
Combination therapies using immuno-dash inhibitors and PGE2 antagonists
|
|
WO2018047109A1
(en)
|
2016-09-09 |
2018-03-15 |
Novartis Ag |
Polycyclic pyridone compounds as antivirals
|
|
US20190247399A1
(en)
|
2016-09-09 |
2019-08-15 |
Tg Therapeutics, Inc. |
Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
|
|
US11077178B2
(en)
|
2016-09-21 |
2021-08-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use
|
|
US11673971B2
(en)
|
2016-09-23 |
2023-06-13 |
Marengo Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
|
CN109844536B
(zh)
|
2016-09-26 |
2023-04-14 |
豪夫迈·罗氏有限公司 |
预测对pd-1轴抑制剂的响应
|
|
EP3518946A4
(en)
|
2016-09-27 |
2020-09-09 |
Board of Regents, The University of Texas System |
METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME
|
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
|
AU2017335839A1
(en)
|
2016-09-29 |
2019-04-18 |
Genentech, Inc. |
Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a taxane
|
|
US10537590B2
(en)
|
2016-09-30 |
2020-01-21 |
Boehringer Ingelheim International Gmbh |
Cyclic dinucleotide compounds
|
|
TN2020000158A1
(en)
|
2016-10-04 |
2022-04-04 |
Merck Sharp & Dohme |
BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
|
|
EP3522923A1
(en)
|
2016-10-06 |
2019-08-14 |
Pfizer Inc |
Dosing regimen of avelumab for the treatment of cancer
|
|
CA3038712A1
(en)
|
2016-10-06 |
2018-04-12 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
JP7041136B2
(ja)
|
2016-10-12 |
2022-03-23 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
Ｔｕｓｃ２免疫療法のための方法および組成物
|
|
WO2018071792A1
(en)
|
2016-10-14 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
|
|
WO2018071576A1
(en)
|
2016-10-14 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of tumors by inhibition of cd300f
|
|
WO2018073753A1
(en)
|
2016-10-18 |
2018-04-26 |
Novartis Ag |
Fused tetracyclic pyridone compounds as antivirals
|
|
CN110114368B
(zh)
|
2016-10-24 |
2024-08-02 |
奥睿尼斯生物科学私人有限公司 |
靶向突变干扰素-γ及其用途
|
|
WO2018077629A1
(en)
|
2016-10-27 |
2018-05-03 |
Herlev Hospital |
New pdl2 compounds
|
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
|
US11555076B2
(en)
|
2016-10-29 |
2023-01-17 |
Genentech, Inc. |
Anti-MIC antibodies and methods of use
|
|
US11124577B2
(en)
|
2016-11-02 |
2021-09-21 |
Engmab Sàrl |
Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
|
|
ES2910832T3
(es)
|
2016-11-07 |
2022-05-13 |
Bristol Myers Squibb Co |
Inmunomoduladores
|
|
EP3538112A4
(en)
|
2016-11-09 |
2020-09-02 |
Musc Foundation for Research Development |
CD38-NAD + REGULATED METABOLIC AXIS IN ANTITUMOR IMMUNOTHERAPY
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
MA46852A
(fr)
|
2016-11-17 |
2019-09-25 |
Univ Texas |
Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20
|
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
WO2018091542A1
(en)
|
2016-11-21 |
2018-05-24 |
Idenix Pharmaceuticals Llc |
Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
|
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
|
US11299469B2
(en)
|
2016-11-29 |
2022-04-12 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
|
BR112019011370A2
(pt)
|
2016-12-01 |
2019-10-15 |
Glaxosmithkline Ip Dev Ltd |
terapia de combinação
|
|
EP3548068A1
(en)
|
2016-12-01 |
2019-10-09 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy
|
|
MA46961A
(fr)
|
2016-12-03 |
2019-10-09 |
Juno Therapeutics Inc |
Procédés de modulation de lymphocytes t modifiés par car
|
|
JP7246309B2
(ja)
|
2016-12-08 |
2023-03-27 |
リクスト・バイオテクノロジー，インコーポレイテッド |
免疫応答を調節するためのオキサビシクロヘプタン
|
|
EP3551226A1
(en)
|
2016-12-12 |
2019-10-16 |
MultiVir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
|
KR20190095921A
(ko)
|
2016-12-12 |
2019-08-16 |
제넨테크, 인크. |
항-pd-l1 항체 및 안티안드로겐을 사용하여 암을 치료하는 방법
|
|
WO2018112364A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating melanoma
|
|
WO2018112360A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating cancer
|
|
US11299530B2
(en)
|
2017-01-05 |
2022-04-12 |
Kahr Medical Ltd. |
SIRP alpha-CD70 fusion protein and methods of use thereof
|
|
WO2018127916A1
(en)
|
2017-01-05 |
2018-07-12 |
Kahr Medical Ltd. |
A pd1-cd70 fusion protein and methods of use thereof
|
|
HRP20220230T1
(hr)
|
2017-01-05 |
2022-04-29 |
Kahr Medical Ltd. |
Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe
|
|
IL267861B2
(en)
|
2017-01-05 |
2025-02-01 |
Kahr Medical Ltd |
PD1-41BBL conjugated protein and methods of using the same
|
|
ES2988845T3
(es)
|
2017-01-09 |
2024-11-21 |
Onkosxcel Therapeutics Llc |
Procedimientos predictivos y diagnósticos para cáncer de próstata
|
|
CN110461847B
(zh)
|
2017-01-25 |
2022-06-07 |
百济神州有限公司 |
(S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
|
|
AU2018212788A1
(en)
|
2017-01-27 |
2019-07-25 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as STING agonists
|
|
WO2018138684A1
(en)
|
2017-01-27 |
2018-08-02 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
WO2018140890A1
(en)
*
|
2017-01-29 |
2018-08-02 |
Zequn Tang |
Methods of immune modulation against foreign and/or auto antigens
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
EP3577133A1
(en)
|
2017-02-06 |
2019-12-11 |
Orionis Biosciences NV |
Targeted chimeric proteins and uses thereof
|
|
WO2018144999A1
(en)
|
2017-02-06 |
2018-08-09 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
|
CA3051986A1
(en)
|
2017-02-10 |
2018-08-16 |
Novartis Ag |
1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer
|
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
CA3054571A1
(en)
|
2017-02-24 |
2018-08-30 |
Board Of Regents,The University Of Texas System |
Assay for detection of early stage pancreatic cancer
|
|
MX2019010086A
(es)
|
2017-02-27 |
2020-02-12 |
Novartis Ag |
Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1.
|
|
JP2020509009A
(ja)
|
2017-02-27 |
2020-03-26 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
キナーゼ阻害剤としての複素環式アミド
|
|
CN110546277B
(zh)
|
2017-03-01 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
|
US20200150125A1
(en)
|
2017-03-12 |
2020-05-14 |
Yeda Research And Development Co., Ltd. |
Methods of diagnosing and prognosing cancer
|
|
WO2018167147A1
(en)
|
2017-03-15 |
2018-09-20 |
F. Hoffmann-La Roche Ag |
Azaindoles as inhibitors of hpk1
|
|
CN110809581A
(zh)
*
|
2017-03-16 |
2020-02-18 |
高山免疫科学股份有限公司 |
Pd-l2变体免疫调节蛋白及其用途
|
|
CA3054068A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
JP7247097B2
(ja)
*
|
2017-03-17 |
2023-03-28 |
バクシム アクチェンゲゼルシャフト |
がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン
|
|
JOP20190218A1
(ar)
|
2017-03-22 |
2019-09-22 |
Boehringer Ingelheim Int |
مركبات ثنائية النيوكليوتيدات حلقية معدلة
|
|
CN108623686A
(zh)
|
2017-03-25 |
2018-10-09 |
信达生物制药(苏州)有限公司 |
抗ox40抗体及其用途
|
|
WO2018176144A1
(en)
*
|
2017-03-29 |
2018-10-04 |
Sunnybrook Research Institute |
Engineered t-cell modulating molecules and methods of using same
|
|
US20180282282A1
(en)
|
2017-03-30 |
2018-10-04 |
Genentech, Inc. |
Isoquinolines as inhibitors of hpk1
|
|
AU2018244935A1
(en)
|
2017-03-30 |
2019-08-15 |
F. Hoffmann-La Roche Ag |
Naphthyridines as inhibitors of HPK1
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
PT3606946T
(pt)
|
2017-04-03 |
2022-10-17 |
Hoffmann La Roche |
Imunoconjugados de um anticorpo anti-pd-1 com uma il-2 mutante ou com il-15
|
|
CN116375876A
(zh)
|
2017-04-05 |
2023-07-04 |
豪夫迈·罗氏有限公司 |
特异性结合pd1和lag3的双特异性抗体
|
|
BR112019021411A2
(pt)
|
2017-04-13 |
2020-05-05 |
Hoffmann La Roche |
métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
|
|
EP3610042A1
(en)
|
2017-04-14 |
2020-02-19 |
H. Hoffnabb-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
|
AU2018256406A1
(en)
|
2017-04-19 |
2019-10-17 |
Marengo Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
JP2020517913A
(ja)
|
2017-04-28 |
2020-06-18 |
ファイブ プライム セラピューティクス， インコーポレイテッド |
Ｃｄ８０細胞外ドメインポリペプチドによる治療方法
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3615566B1
(en)
|
2017-04-28 |
2023-12-20 |
Marengo Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
AR111658A1
(es)
|
2017-05-05 |
2019-08-07 |
Novartis Ag |
2-quinolinonas tricíclicas como agentes antibacteriales
|
|
CA3063359A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
EP3621624B1
(en)
|
2017-05-12 |
2023-08-30 |
Merck Sharp & Dohme LLC |
Cyclic di-nucleotide compounds as sting agonists
|
|
WO2018213424A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
JOP20190279A1
(ar)
|
2017-05-31 |
2019-11-28 |
Novartis Ag |
الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
|
|
KR20250139417A
(ko)
|
2017-05-31 |
2025-09-23 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
|
US20200181274A1
(en)
|
2017-06-01 |
2020-06-11 |
Novartis Ag |
Bispecific antibodies that bind cd 123 cd3
|
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
|
KR20200054160A
(ko)
|
2017-06-02 |
2020-05-19 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
|
|
JP2020522562A
(ja)
|
2017-06-06 |
2020-07-30 |
ストキューブ アンド シーオー．， インコーポレイテッド |
Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
|
|
WO2018225093A1
(en)
|
2017-06-07 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
|
EP3634483A1
(en)
|
2017-06-09 |
2020-04-15 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy
|
|
JP7657023B2
(ja)
|
2017-06-09 |
2025-04-04 |
プロビデンス ヘルス アンド サービシーズ－オレゴン |
がんの処置のための腫瘍反応性ヒトｔ細胞の同定のためのｃｄ３９およびｃｄ１０３の使用
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
AU2018287519B2
(en)
|
2017-06-22 |
2021-07-22 |
Novartis Ag |
IL-1beta binding antibodies for use in treating cancer
|
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
EP3641812A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
WO2018237153A1
(en)
|
2017-06-23 |
2018-12-27 |
Bristol-Myers Squibb Company |
Immunomodulators acting as antagonists of pd-1
|
|
TW202515616A
(zh)
|
2017-06-26 |
2025-04-16 |
英屬開曼群島商百濟神州有限公司 |
抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
|
|
AU2018292618A1
(en)
|
2017-06-27 |
2019-12-19 |
Novartis Ag |
Dosage regimens for anti-TIM-3 antibodies and uses thereof
|
|
AU2018291032A1
(en)
|
2017-06-29 |
2020-01-16 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
|
US20210145771A1
(en)
|
2017-07-03 |
2021-05-20 |
Glaxosmithkline Intellectual Property Development Limited |
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
|
US20200140383A1
(en)
|
2017-07-03 |
2020-05-07 |
Glaxosmithkline Intellectual Property Development Limited |
2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
|
US11293066B2
(en)
|
2017-07-18 |
2022-04-05 |
Institut Gustave Roussy |
Method for assessing the response to PD-1/PDL-1 targeting drugs
|
|
KR20250025039A
(ko)
|
2017-07-20 |
2025-02-20 |
노파르티스 아게 |
항-lag-3 항체의 투여 요법 및 그의 용도
|
|
IL271888B2
(en)
|
2017-07-21 |
2024-09-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
US11285131B2
(en)
|
2017-08-04 |
2022-03-29 |
Merck Sharp & Dohme Corp. |
Benzo[b]thiophene STING agonists for cancer treatment
|
|
RU2020109328A
(ru)
|
2017-08-04 |
2021-09-06 |
Мерк Шарп И Доум Корп. |
Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака
|
|
JP7290013B2
(ja)
|
2017-08-04 |
2023-06-13 |
ジェンマブ エー／エス |
Ｐｄ－ｌ１およびｃｄ１３７に結合する結合物質ならびにその使用
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
CN109456405B
(zh)
*
|
2017-09-06 |
2022-02-08 |
上海交通大学医学院附属仁济医院 |
一种去棕榈酰化pd-l1蛋白质及其制备方法和应用
|
|
TW201922721A
(zh)
|
2017-09-07 |
2019-06-16 |
英商葛蘭素史克智慧財產發展有限公司 |
化學化合物
|
|
WO2019051127A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
|
US20200216542A1
(en)
|
2017-09-20 |
2020-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
|
JP7257393B2
(ja)
|
2017-10-03 |
2023-04-13 |
ブリストル－マイヤーズ スクイブ カンパニー |
免疫調節剤
|
|
JP2020536106A
(ja)
|
2017-10-05 |
2020-12-10 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
Ｈｉｖの処置に有用なインターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
|
|
BR112020006780A2
(pt)
|
2017-10-05 |
2020-10-06 |
Glaxosmithkline Intellectual Property Development Limited |
moduladores do estimulador de genes do interferon (sting)
|
|
US12178787B2
(en)
|
2017-10-12 |
2024-12-31 |
Board Of Regents, The University Of Texas System |
T cell receptors for immunotherapy
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
UA129446C2
(uk)
|
2017-10-13 |
2025-04-30 |
Гарпун Терап'Ютікс, Інк. |
Триспецифічні білки і способи їх застосування
|
|
EP3697434A1
(en)
|
2017-10-18 |
2020-08-26 |
Vivia Biotech, S.L. |
Bite-activated car-t cells
|
|
RU2022103533A
(ru)
|
2017-10-20 |
2022-03-10 |
Бионтек Рна Фармасьютикалс Гмбх (Biontech Rna Pharmaceuticals Gmbh) |
Приготовление и хранение липосомальных РНК-составов, подходящих для терапии
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
BR112020008638A2
(pt)
|
2017-11-01 |
2020-10-20 |
Juno Therapeutics Inc |
receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
|
|
CA3080904A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
|
WO2019089412A1
(en)
|
2017-11-01 |
2019-05-09 |
Merck Sharp & Dohme Corp. |
Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
|
AU2018359967A1
(en)
|
2017-11-06 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
EP3707165A4
(en)
|
2017-11-07 |
2021-09-08 |
The Board of Regents of The University of Texas System |
TARGETING LILRB4 WITH CAR-T OR CAR-NK CELLS IN CANCER TREATMENT
|
|
WO2019099294A1
(en)
|
2017-11-14 |
2019-05-23 |
Merck Sharp & Dohme Corp. |
Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
|
CA3082108A1
(en)
|
2017-11-14 |
2019-05-23 |
Merck Sharp & Dohme Corp. |
Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
|
CA3082287C
(en)
|
2017-11-14 |
2023-02-28 |
Pfizer Inc. |
Ezh2 inhibitor combination therapies
|
|
AU2018368731A1
(en)
|
2017-11-16 |
2020-05-14 |
Novartis Ag |
Combination therapies
|
|
JOP20200131A1
(ar)
|
2017-11-17 |
2020-05-28 |
Merck Sharp & Dohme |
أجسام مضادة خاصة بنسخة تشبه جلوبيولين مناعي 3 (ilt3) واستخدامتها
|
|
US20210079015A1
(en)
|
2017-11-17 |
2021-03-18 |
Novartis Ag |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
|
CN111741746A
(zh)
|
2017-11-29 |
2020-10-02 |
乌第有限合伙公司 |
治疗自身免疫性疾病的方法
|
|
TW201925782A
(zh)
|
2017-11-30 |
2019-07-01 |
瑞士商諾華公司 |
靶向bcma之嵌合抗原受體及其用途
|
|
JP7348899B2
(ja)
|
2017-12-08 |
2023-09-21 |
マレンゴ・セラピューティクス，インコーポレーテッド |
多重特異性分子及びその使用
|
|
AU2018386222B2
(en)
|
2017-12-15 |
2023-04-20 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
|
CN111433210A
(zh)
|
2017-12-20 |
2020-07-17 |
诺华股份有限公司 |
作为抗病毒药的稠合三环吡唑并-二氢吡嗪基-吡啶酮化合物
|
|
WO2019125974A1
(en)
|
2017-12-20 |
2019-06-27 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
|
CN109970856B
(zh)
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
EP3735417A1
(en)
|
2018-01-03 |
2020-11-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
TW201930591A
(zh)
|
2018-01-08 |
2019-08-01 |
瑞士商諾華公司 |
用於與嵌合抗原受體療法併用之免疫增強rna
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
US11246908B2
(en)
*
|
2018-01-10 |
2022-02-15 |
The Johns Hopkins University |
Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
|
|
AU2019207895A1
(en)
*
|
2018-01-12 |
2020-06-18 |
Amgen Inc. |
Anti-PD-1 antibodies and methods of treatment
|
|
WO2019148089A1
(en)
|
2018-01-26 |
2019-08-01 |
Orionis Biosciences Inc. |
Xcr1 binding agents and uses thereof
|
|
EP3746480A1
(en)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
EP3746117A1
(en)
|
2018-01-31 |
2020-12-09 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
|
MX2020008208A
(es)
|
2018-02-05 |
2020-11-09 |
Orionis Biosciences Inc |
Agentes de unión a fibroblastos y uso de estos.
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
WO2019166951A1
(en)
|
2018-02-28 |
2019-09-06 |
Novartis Ag |
Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
|
|
SG11202008696RA
(en)
|
2018-03-12 |
2020-10-29 |
Inst Nat Sante Rech Med |
Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
|
|
US12215116B2
(en)
|
2018-03-13 |
2025-02-04 |
Merck Sharp & Dohme Llc |
Arginase inhibitors and methods of use
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
MX394121B
(es)
|
2018-03-14 |
2025-03-24 |
Surface Oncology Inc |
Anticuerpos que se unen a cd39 y sus usos
|
|
AU2019322487B2
(en)
|
2018-03-19 |
2024-04-18 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
|
|
BR112020018918A2
(pt)
|
2018-03-22 |
2021-01-05 |
Surface Oncology, Inc. |
Anticorpos anti-il-27 e usos dos mesmos
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
EP4066851A1
(en)
|
2018-03-25 |
2022-10-05 |
SNIPR Biome ApS. |
Treating & preventing microbial infections
|
|
JP2021519270A
(ja)
|
2018-03-27 |
2021-08-10 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
２−アザ−ヒポキサンチンまたは６ｈ−ピラゾロ［１，５−ｄ］［１，２，４］トリアジン−７−オンをｓｔｉｎｇアゴニストとして含む環式ジヌクレオチド化合物
|
|
JP2021519279A
(ja)
|
2018-03-27 |
2021-08-10 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
修飾環式ジヌクレオチド化合物
|
|
BR112020019251A2
(pt)
|
2018-03-27 |
2021-01-12 |
Board Of Regents, The University Of Texas System |
Compostos com atividade anti-tumor contra células de câncer com mutações de her2 exon 19
|
|
CN108530537B
(zh)
*
|
2018-03-29 |
2019-07-02 |
中国人民解放军军事科学院军事医学研究院 |
Pd-1/pd-l1信号通路抑制剂
|
|
WO2019195124A1
(en)
|
2018-04-03 |
2019-10-10 |
Merck Sharp & Dohme Corp. |
Benzothiophenes and related compounds as sting agonists
|
|
WO2019195063A1
(en)
|
2018-04-03 |
2019-10-10 |
Merck Sharp & Dohme Corp. |
Aza-benzothiophene compounds as sting agonists
|
|
WO2019193540A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Heteroaryl derivatives of formula (i) as atf4 inhibitors
|
|
WO2019193541A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
MX2020010913A
(es)
|
2018-04-17 |
2021-01-08 |
Celldex Therapeutics Inc |
Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
|
|
AU2019256539A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
|
CA3097625A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
CN112105733B
(zh)
|
2018-04-19 |
2024-10-29 |
查美特制药公司 |
合成rig-i样受体激动剂
|
|
WO2019204179A1
(en)
|
2018-04-20 |
2019-10-24 |
Merck Sharp & Dohme Corp. |
Novel substituted rig-i agonists: compositions and methods thereof
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
WO2019211489A1
(en)
|
2018-05-04 |
2019-11-07 |
Merck Patent Gmbh |
COMBINED INHIBITION OF PD-1/PD-L1, TGFβ AND DNA-PK FOR THE TREATMENT OF CANCER
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
WO2019231870A1
(en)
|
2018-05-31 |
2019-12-05 |
Merck Sharp & Dohme Corp. |
Novel substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
TW202017569A
(zh)
|
2018-05-31 |
2020-05-16 |
美商佩樂敦治療公司 |
用於抑制cd73之組合物及方法
|
|
JP7490574B2
(ja)
|
2018-05-31 |
2024-05-27 |
ノバルティス アーゲー |
Ｂ型肝炎抗体
|
|
TWI848951B
(zh)
|
2018-06-01 |
2024-07-21 |
瑞士商諾華公司 |
針對ｂｃｍａ之結合分子及其用途
|
|
WO2019232528A1
(en)
|
2018-06-01 |
2019-12-05 |
Xencor, Inc. |
Dosing of a bispecific antibody that bind cd123 and cd3
|
|
US11555071B2
(en)
|
2018-06-03 |
2023-01-17 |
Lamkap Bio Beta Ltd. |
Bispecific antibodies against CEACAM5 and CD47
|
|
CN112566643A
(zh)
|
2018-06-12 |
2021-03-26 |
加利福尼亚大学董事会 |
用于治疗癌症的单链双特异性嵌合抗原受体
|
|
AU2019284911A1
(en)
|
2018-06-13 |
2020-12-17 |
Novartis Ag |
BCMA chimeric antigen receptors and uses thereof
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
CA3103983A1
(en)
|
2018-06-19 |
2019-12-26 |
Biontech Us Inc. |
Neoantigens and uses thereof
|
|
WO2019245890A1
(en)
|
2018-06-20 |
2019-12-26 |
Merck Sharp & Dohme Corp. |
Arginase inhibitors and methods of use
|
|
EP3810653A1
(en)
|
2018-06-23 |
2021-04-28 |
F. Hoffmann-La Roche AG |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
JP2021529741A
(ja)
|
2018-06-25 |
2021-11-04 |
イモデュロン セラピューティクス リミテッド |
がん治療
|
|
WO2020005068A2
(en)
|
2018-06-29 |
2020-01-02 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
JP2021529814A
(ja)
|
2018-07-09 |
2021-11-04 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
化学化合物
|
|
CA3103385A1
(en)
|
2018-07-10 |
2020-01-16 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
SG11202013167UA
(en)
|
2018-07-11 |
2021-01-28 |
Kahr Medical Ltd |
SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
|
|
SG11202013170RA
(en)
|
2018-07-11 |
2021-01-28 |
Kahr Medical Ltd |
Pd1-4-1bbl variant fusion protein and methods of use thereof
|
|
MX2021000558A
(es)
|
2018-07-18 |
2021-04-13 |
Genentech Inc |
Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino.
|
|
US20210301020A1
(en)
|
2018-07-24 |
2021-09-30 |
Amgen Inc. |
Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
|
|
WO2020020444A1
(en)
|
2018-07-24 |
2020-01-30 |
Biontech Rna Pharmaceuticals Gmbh |
Individualized vaccines for cancer
|
|
JP7386842B2
(ja)
|
2018-07-24 |
2023-11-27 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
ナフチリジン化合物およびその使用
|
|
TW202019905A
(zh)
|
2018-07-24 |
2020-06-01 |
瑞士商赫孚孟拉羅股份公司 |
異喹啉化合物及其用途
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
WO2020031107A1
(en)
|
2018-08-08 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
|
KR102715542B1
(ko)
|
2018-08-20 |
2024-10-08 |
화이자 인코포레이티드 |
항-gdf15 항체, 조성물 및 사용 방법
|
|
WO2020044206A1
(en)
|
2018-08-29 |
2020-03-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors for use in the treatment cancer
|
|
KR20210049814A
(ko)
*
|
2018-08-29 |
2021-05-06 |
파이브 프라임 테라퓨틱스, 인크. |
Cd80 세포외 도메인 fc 융합 단백질 투약 요법
|
|
WO2020044252A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Dosage regimes for anti-m-csf antibodies and uses thereof
|
|
WO2020051099A1
(en)
|
2018-09-03 |
2020-03-12 |
Genentech, Inc. |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
|
WO2020049534A1
(en)
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
|
BR112021004287A2
(pt)
|
2018-09-07 |
2021-08-03 |
Pfizer Inc. |
anticorpos anti-avss8 e composições e usos dos mesmos
|
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
|
CA3112326A1
(en)
|
2018-09-12 |
2020-03-19 |
Novartis Ag |
Antiviral pyridopyrazinedione compounds
|
|
WO2020055702A1
(en)
|
2018-09-13 |
2020-03-19 |
Merck Sharp & Dohme Corp. |
Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
|
|
WO2020061129A1
(en)
|
2018-09-19 |
2020-03-26 |
President And Fellows Of Harvard College |
Compositions and methods for labeling and modulation of cells in vitro and in vivo
|
|
JP7618950B2
(ja)
|
2018-09-19 |
2025-01-22 |
インサーム （インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル） |
免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
|
|
WO2020061377A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof
|
|
CN113544144A
(zh)
|
2018-09-19 |
2021-10-22 |
高山免疫科学股份有限公司 |
变体cd80融合蛋白和相关构建体的方法和用途
|
|
KR20210063330A
(ko)
|
2018-09-19 |
2021-06-01 |
제넨테크, 인크. |
방광암에 대한 치료 및 진단 방법
|
|
AU2019342133B8
(en)
|
2018-09-21 |
2025-08-07 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
EP3856771A4
(en)
|
2018-09-25 |
2022-06-29 |
Harpoon Therapeutics, Inc. |
Dll3 binding proteins and methods of use
|
|
CN113164777B
(zh)
|
2018-09-27 |
2024-12-13 |
马伦戈治疗公司 |
Csf1r/ccr2多特异性抗体
|
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
|
EP3856782A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
CA3113379A1
(en)
|
2018-09-29 |
2020-04-02 |
Novartis Ag |
Process of manufacture of a compound for inhibiting the activity of shp2
|
|
CN113454070A
(zh)
|
2018-09-30 |
2021-09-28 |
豪夫迈·罗氏有限公司 |
噌啉化合物及用于hpk1依赖性疾患诸如癌症的治疗
|
|
EP3860578A1
(en)
|
2018-10-01 |
2021-08-11 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
|
TW202024053A
(zh)
|
2018-10-02 |
2020-07-01 |
美商建南德克公司 |
異喹啉化合物及其用途
|
|
CN113166062A
(zh)
|
2018-10-03 |
2021-07-23 |
豪夫迈·罗氏有限公司 |
8-氨基异喹啉化合物及其用途
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
CR20210239A
(es)
|
2018-10-12 |
2021-12-15 |
Xencor Inc |
Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
|
|
JP2022504905A
(ja)
|
2018-10-16 |
2022-01-13 |
ノバルティス アーゲー |
標的化療法に対する応答を予測するためのバイオマーカーとしての単独の又は免疫マーカーと組み合わせた腫瘍突然変異負荷
|
|
US12291570B2
(en)
|
2018-10-17 |
2025-05-06 |
Biolinerx Ltd. |
Treatment of metastatic pancreatic adenocarcinoma
|
|
US12152019B2
(en)
|
2018-10-17 |
2024-11-26 |
Merck Sharp & Dohme Llc |
Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
MX2021004348A
(es)
|
2018-10-18 |
2021-05-28 |
Genentech Inc |
Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
|
|
JP2022505524A
(ja)
|
2018-10-22 |
2022-01-14 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
投薬
|
|
KR20210084552A
(ko)
|
2018-10-29 |
2021-07-07 |
위스콘신 얼럼나이 리서어치 화운데이션 |
향상된 암 면역요법을 위한 면역관문 억제제와 복합체화된 덴드리틱 폴리머
|
|
US11564995B2
(en)
|
2018-10-29 |
2023-01-31 |
Wisconsin Alumni Research Foundation |
Peptide-nanoparticle conjugates
|
|
WO2020089811A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
WO2020092839A1
(en)
|
2018-10-31 |
2020-05-07 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
EP3873540A4
(en)
|
2018-10-31 |
2022-07-27 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
AU2019374103A1
(en)
|
2018-11-01 |
2021-05-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
|
|
AU2019372331A1
(en)
|
2018-11-01 |
2021-05-27 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
|
|
EP3873464B1
(en)
|
2018-11-01 |
2025-07-30 |
Merck Sharp & Dohme LLC |
Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
EP3877366A4
(en)
|
2018-11-06 |
2022-08-24 |
Merck Sharp & Dohme Corp. |
NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLAMINE-2,3-DIOXYGENASE INHIBITORS
|
|
US12410225B2
(en)
|
2018-11-08 |
2025-09-09 |
Orionis Biosciences, Inc |
Modulation of dendritic cell lineages
|
|
JP2022507495A
(ja)
|
2018-11-16 |
2022-01-18 |
アーキュール・インコーポレイテッド |
癌治療のための医薬の組合せ
|
|
CA3120118A1
(en)
|
2018-11-16 |
2020-05-22 |
Juno Therapeutics, Inc. |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
|
WO2020106621A1
(en)
|
2018-11-19 |
2020-05-28 |
Board Of Regents, The University Of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
|
KR20210093964A
(ko)
|
2018-11-20 |
2021-07-28 |
머크 샤프 앤드 돔 코포레이션 |
치환된 아미노 트리아졸로피리미딘 및 아미노 트리아졸로피라진 아데노신 수용체 길항제, 제약 조성물 및 그의 용도
|
|
WO2020106560A1
(en)
|
2018-11-20 |
2020-05-28 |
Merck Sharp & Dohme Corp. |
Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
|
|
WO2020109328A1
(en)
|
2018-11-26 |
2020-06-04 |
Debiopharm International S.A. |
Combination treatment of hiv infections
|
|
US20220018828A1
(en)
|
2018-11-28 |
2022-01-20 |
Inserm (Institut National De La Santé Et La Recherche Médicale |
Methods and kit for assaying lytic potential of immune effector cells
|
|
EP3886845B1
(en)
|
2018-11-28 |
2024-09-04 |
Merck Sharp & Dohme LLC |
Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors
|
|
AU2019386140A1
(en)
|
2018-11-28 |
2021-06-24 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
CN113316455A
(zh)
|
2018-11-29 |
2021-08-27 |
得克萨斯大学体系董事会 |
用于离体扩增自然杀伤细胞的方法及其用途
|
|
WO2020113194A2
(en)
|
2018-11-30 |
2020-06-04 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
|
CR20210271A
(es)
|
2018-11-30 |
2021-07-14 |
Merck Sharp & Dohme |
Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso
|
|
WO2020110056A1
(en)
|
2018-11-30 |
2020-06-04 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds useful in hiv therapy
|
|
US11034710B2
(en)
|
2018-12-04 |
2021-06-15 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
|
EP4198057A1
(en)
|
2018-12-05 |
2023-06-21 |
F. Hoffmann-La Roche AG |
Diagnostic methods and compositions for cancer immunotherapy
|
|
EP3891270A1
(en)
|
2018-12-07 |
2021-10-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
|
CN113195467A
(zh)
|
2018-12-11 |
2021-07-30 |
施万生物制药研发Ip有限责任公司 |
适用作alk5抑制剂的萘啶和喹啉衍生物
|
|
MA54469A
(fr)
|
2018-12-13 |
2021-10-20 |
Surface Oncology Inc |
Anticorps anti-il-27 et leurs utilisations
|
|
US20220047556A1
(en)
|
2018-12-17 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sulconazole as a furin inhibitor
|
|
US12240867B2
(en)
|
2018-12-18 |
2025-03-04 |
Merck Sharp & Dohme Llc |
Arginase inhibitors and methods of use
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
US11618776B2
(en)
|
2018-12-20 |
2023-04-04 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
|
|
CN113166762B
(zh)
|
2018-12-21 |
2025-01-14 |
瓦莱里奥治疗公司 |
新的偶联核酸分子及其用途
|
|
EP3897613A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
|
EP3898674A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
|
AU2019406840A1
(en)
|
2018-12-21 |
2021-06-03 |
Novartis Ag |
Use of IL-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
|
|
KR20210107731A
(ko)
|
2018-12-21 |
2021-09-01 |
노파르티스 아게 |
Pmel17에 대한 항체 및 이의 접합체
|
|
CA3124837A1
(en)
|
2019-01-14 |
2020-07-23 |
Genentech, Inc. |
Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
|
|
JP7645185B2
(ja)
|
2019-01-15 |
2025-03-13 |
アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル |
変異したインターロイキン－３４（ｉｌ－３４）ポリペプチドおよび治療におけるその使用
|
|
MX2021009087A
(es)
|
2019-01-29 |
2021-09-08 |
Juno Therapeutics Inc |
Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1).
|
|
JP2022519649A
(ja)
|
2019-02-08 |
2022-03-24 |
ジェネンテック， インコーポレイテッド |
がんの診断および治療方法
|
|
CA3127502A1
(en)
|
2019-02-12 |
2020-08-20 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
EP3923940B1
(en)
|
2019-02-12 |
2025-12-03 |
Novartis AG |
Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
|
|
ES2982474T3
(es)
|
2019-02-15 |
2024-10-16 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
|
|
ES3032659T3
(en)
|
2019-02-15 |
2025-07-23 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
|
CN119661722A
(zh)
|
2019-02-21 |
2025-03-21 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
EP3927747A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
SG11202108691TA
(en)
|
2019-03-12 |
2021-09-29 |
BioNTech SE |
Therapeutic rna for prostate cancer
|
|
CA3130446A1
(en)
|
2019-03-14 |
2020-09-17 |
Genentech, Inc. |
Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
|
|
US20220184121A1
(en)
|
2019-03-18 |
2022-06-16 |
The Regents Of The University Of California |
Augmentation of t-cell activation by oscillatory forces and engineered antigen-presenting cells
|
|
KR20220012839A
(ko)
|
2019-03-19 |
2022-02-04 |
펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론 |
Omomyc와 pd-1 또는 ctla-4에 결합하는 항체를 이용한 암 치료용 조합 요법
|
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
|
WO2020198077A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
AU2020254520A1
(en)
|
2019-03-29 |
2021-09-16 |
Genentech, Inc. |
Modulators of cell surface protein interactions and methods and compositions related to same
|
|
US20220177978A1
(en)
|
2019-04-02 |
2022-06-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
PH12021552477A1
(en)
|
2019-04-04 |
2022-07-18 |
Boehringer Ingelheim Animal Health Usa Inc |
Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof
|
|
EP3946324B1
(en)
|
2019-04-04 |
2025-07-30 |
Merck Sharp & Dohme LLC |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
|
WO2020200472A1
(en)
|
2019-04-05 |
2020-10-08 |
Biontech Rna Pharmaceuticals Gmbh |
Preparation and storage of liposomal rna formulations suitable for therapy
|
|
WO2020208060A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
|
US20220177912A1
(en)
*
|
2019-04-12 |
2022-06-09 |
The Methodist Hospital |
Therapeutic particles that enable antigen presenting cells to attack cancer cells
|
|
US20220220480A1
(en)
|
2019-04-17 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
|
BR112021020867A2
(pt)
|
2019-04-19 |
2022-01-04 |
Genentech Inc |
Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
|
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
|
AU2020268199B2
(en)
|
2019-05-09 |
2025-08-21 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for the production of hepatocytes
|
|
EP3969452A1
(en)
|
2019-05-16 |
2022-03-23 |
Stingthera, Inc. |
Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
|
|
JP2022533390A
(ja)
|
2019-05-16 |
2022-07-22 |
スティングセラ インコーポレイテッド |
オキソアクリジニル酢酸誘導体および使用方法
|
|
CN114096240A
(zh)
|
2019-05-17 |
2022-02-25 |
癌症预防制药股份有限公司 |
用于治疗家族性腺瘤性息肉病的方法
|
|
KR20220010500A
(ko)
|
2019-05-20 |
2022-01-25 |
비온테크 에스이 |
난소암 치료용 rna
|
|
US20220298225A1
(en)
|
2019-06-03 |
2022-09-22 |
The University Of Chicago |
Methods and compositions for treating cancer with collagen binding drug carriers
|
|
WO2020247973A1
(en)
|
2019-06-03 |
2020-12-10 |
The University Of Chicago |
Methods and compositions for treating cancer with cancer-targeted adjuvants
|
|
WO2020255011A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
|
JP2022537324A
(ja)
|
2019-06-18 |
2022-08-25 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１抗体の組合せ
|
|
EP3990635A1
(en)
|
2019-06-27 |
2022-05-04 |
Rigontec GmbH |
Design method for optimized rig-i ligands
|
|
US11529350B2
(en)
|
2019-07-03 |
2022-12-20 |
Sumitomo Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
EP3999079A4
(en)
*
|
2019-07-19 |
2024-04-03 |
Memorial Sloan Kettering Cancer Center |
Fusion polypeptide for immunotherapy
|
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
US12036204B2
(en)
|
2019-07-26 |
2024-07-16 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
US20220257698A1
(en)
|
2019-08-02 |
2022-08-18 |
Lanthiopep B.V. |
Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
|
|
KR20220056176A
(ko)
|
2019-08-02 |
2022-05-04 |
메르사나 테라퓨틱스, 인코포레이티드 |
암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
CN114127121B
(zh)
|
2019-08-12 |
2025-04-11 |
北京恩瑞尼生物科技股份有限公司 |
用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
|
|
JP2022548484A
(ja)
|
2019-09-16 |
2022-11-21 |
サーフィス オンコロジー インコーポレイテッド |
抗ｃｄ３９抗体の組成物及び方法
|
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
MX2022003192A
(es)
|
2019-09-18 |
2022-04-11 |
Novartis Ag |
Proteinas de fusion nkg2d y sus usos.
|
|
US12441807B2
(en)
|
2019-09-18 |
2025-10-14 |
Lamkap Bio Alpha AG |
Bispecific antibodies against CEACAM5 and CD3
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
TW202521984A
(zh)
|
2019-09-25 |
2025-06-01 |
美商表面腫瘤學有限責任公司 |
抗ｉｌ－２７抗體及其用途
|
|
WO2021061898A1
(en)
|
2019-09-26 |
2021-04-01 |
Novartis Ag |
Antiviral pyrazolopyridinone compounds
|
|
PH12022550671A1
(en)
|
2019-09-27 |
2023-05-29 |
Glaxosmithkline Ip Dev Ltd |
Antigen binding proteins
|
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
|
CA3157024A1
(en)
|
2019-10-03 |
2021-04-08 |
Xencor, Inc. |
Targeted il-12 heterodimeric fc-fusion proteins
|
|
US20220363776A1
(en)
|
2019-10-04 |
2022-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
CN114786680A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
Tim-3抑制剂及其用途
|
|
MX2022004825A
(es)
|
2019-10-23 |
2022-10-10 |
Regeneron Pharma |
Agonistas sintéticos del receptor similar a rig i.
|
|
AU2020373913B2
(en)
|
2019-10-28 |
2024-04-18 |
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences |
Five-membered heterocyclic oxocarboxylic acid compound and medical use thereof
|
|
KR20220092540A
(ko)
|
2019-10-29 |
2022-07-01 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
암을 치료하기 위한 pd-1 길항제, vegfr/fgfr/ret 티로신 키나제 억제제 및 cbp/베타-카테닌 억제제의 조합물
|
|
US20220380765A1
(en)
|
2019-11-02 |
2022-12-01 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
|
US20220389103A1
(en)
|
2019-11-06 |
2022-12-08 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
|
TWI895295B
(zh)
|
2019-11-12 |
2025-09-01 |
美商方得生醫療公司 |
偵測編碼新生抗原之融合基因之方法
|
|
CN114728905B
(zh)
|
2019-11-13 |
2025-08-01 |
基因泰克公司 |
治疗性化合物及使用方法
|
|
JP2023502264A
(ja)
|
2019-11-22 |
2023-01-23 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
固体用量医薬組成物
|
|
JP2023502662A
(ja)
|
2019-11-22 |
2023-01-25 |
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー |
Ａｌｋ５阻害剤としての置換１，５－ナフチリジンまたはキノリン
|
|
CN114945382A
(zh)
|
2019-11-26 |
2022-08-26 |
诺华股份有限公司 |
Cd19和cd22嵌合抗原受体及其用途
|
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
JP2023504568A
(ja)
|
2019-12-04 |
2023-02-03 |
オルナ セラピューティクス インコーポレイテッド |
環状ｒｎａ組成物及び方法
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
EP4069683A1
(en)
|
2019-12-06 |
2022-10-12 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
|
EP4076443B1
(en)
|
2019-12-17 |
2025-09-10 |
Merck Sharp & Dohme LLC |
Substituted 1,3,8-triazaspiro[4,5]decane-2,4-dione compound as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors
|
|
CN114981265B
(zh)
|
2019-12-18 |
2025-01-03 |
Ctxt私人有限公司 |
化合物
|
|
MX2022007759A
(es)
|
2019-12-20 |
2022-07-19 |
Novartis Ag |
Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
|
|
CN113045655A
(zh)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
抗ox40抗体及其用途
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
JP2023510737A
(ja)
|
2020-01-06 |
2023-03-15 |
ブリストル－マイヤーズ スクイブ カンパニー |
免疫調節剤
|
|
JP2023509516A
(ja)
|
2020-01-07 |
2023-03-08 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
がん治療のための改良型ヒトメチルチオアデノシン／アデノシン枯渇酵素変種
|
|
EP4087583A4
(en)
|
2020-01-07 |
2024-01-24 |
Merck Sharp & Dohme LLC |
Arginase inhibitors and methods of use
|
|
EP4090335A1
(en)
|
2020-01-17 |
2022-11-23 |
Novartis AG |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
US20230123454A1
(en)
*
|
2020-01-23 |
2023-04-20 |
Genexine, Inc. |
Fusion protein comprising pd-l1 protein and use thereof
|
|
WO2021155042A1
(en)
|
2020-01-28 |
2021-08-05 |
Genentech, Inc. |
Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer
|
|
EP4096708A1
(en)
|
2020-01-31 |
2022-12-07 |
Genentech, Inc. |
Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
|
|
EP4107173A1
(en)
|
2020-02-17 |
2022-12-28 |
Board of Regents, The University of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
EP4110818A1
(en)
|
2020-02-26 |
2023-01-04 |
Biograph 55, Inc. |
C19 c38 bispecific antibodies
|
|
EP4110341A2
(en)
|
2020-02-28 |
2023-01-04 |
Novartis AG |
A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor
|
|
TW202146452A
(zh)
|
2020-02-28 |
2021-12-16 |
瑞士商諾華公司 |
結合ｃｄ１２３和ｃｄ３之雙特異性抗體的給藥
|
|
US20230117328A1
(en)
|
2020-03-03 |
2023-04-20 |
Array Biopharma Inc. |
Methods to treat cancer using (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
|
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
|
MX2022011677A
(es)
|
2020-03-20 |
2023-01-11 |
Orna Therapeutics Inc |
Composiciones y métodos de arn circular.
|
|
CN115362166A
(zh)
|
2020-03-30 |
2022-11-18 |
百时美施贵宝公司 |
免疫调节剂
|
|
JP2023519673A
(ja)
|
2020-03-31 |
2023-05-12 |
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー |
置換ピリミジンおよび使用方法
|
|
MY210304A
(en)
|
2020-04-02 |
2025-09-10 |
Mersana Therapeutics Inc |
Antibody drug conjugates comprising sting agonists
|
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
|
KR20230009386A
(ko)
|
2020-04-10 |
2023-01-17 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
|
|
CA3171597A1
(en)
|
2020-04-14 |
2021-10-21 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
CN115698075A
(zh)
|
2020-04-14 |
2023-02-03 |
葛兰素史密斯克莱知识产权发展有限公司 |
涉及抗icos和抗pd1抗体，任选地进一步涉及抗tim3抗体的癌症的组合治疗
|
|
TW202206100A
(zh)
|
2020-04-27 |
2022-02-16 |
美商西健公司 |
癌症之治療
|
|
CN115885050A
(zh)
|
2020-04-28 |
2023-03-31 |
基因泰克公司 |
用于非小细胞肺癌免疫疗法的方法和组合物
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
JP2023524257A
(ja)
|
2020-05-05 |
2023-06-09 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ－１軸阻害剤に対する応答の予測
|
|
CN115836054B
(zh)
|
2020-05-06 |
2024-12-10 |
默沙东有限责任公司 |
Il4i1抑制剂和使用方法
|
|
CN115812077A
(zh)
|
2020-05-08 |
2023-03-17 |
高山免疫科学股份有限公司 |
April和baff抑制性免疫调节蛋白及其使用方法
|
|
CN115803084A
(zh)
|
2020-05-21 |
2023-03-14 |
得克萨斯大学体系董事会 |
具有vgll1特异性的t细胞受体和其用途
|
|
JP2023528017A
(ja)
|
2020-05-26 |
2023-07-03 |
アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） |
重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用
|
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
|
EP4165041A1
(en)
|
2020-06-10 |
2023-04-19 |
Theravance Biopharma R&D IP, LLC |
Naphthyridine derivatives useful as alk5 inhibitors
|
|
JP2023529206A
(ja)
|
2020-06-12 |
2023-07-07 |
ジェネンテック， インコーポレイテッド |
がん免疫療法のための方法及び組成物
|
|
EP4164627A1
(en)
|
2020-06-16 |
2023-04-19 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
|
AR122644A1
(es)
|
2020-06-19 |
2022-09-28 |
Onxeo |
Nuevas moléculas de ácido nucleico conjugado y sus usos
|
|
MX2022015852A
(es)
|
2020-06-23 |
2023-01-24 |
Novartis Ag |
Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
|
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
MX2023000197A
(es)
|
2020-07-07 |
2023-02-22 |
BioNTech SE |
Arn terapeutico para el cancer positivo para vph.
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
EP4188416A4
(en)
*
|
2020-07-27 |
2024-08-21 |
Arizona Board of Regents on behalf of the University of Arizona |
MULTIFUNCTIONAL IMMUNOGLOBULIN-FOLDED POLYPEPTIDES FROM SUBSTITUTION TRANSLATIONAL INITIATION AND TERMINATION
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
GB2616354A
(en)
|
2020-08-26 |
2023-09-06 |
Marengo Therapeutics Inc |
Methods of detecting TRBC1 or TRBC2
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
WO2022049526A1
(en)
|
2020-09-02 |
2022-03-10 |
Pharmabcine Inc. |
Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer
|
|
TW202228727A
(zh)
|
2020-10-01 |
2022-08-01 |
德商拜恩迪克公司 |
適用於治療之微脂體ｒｎａ調配物之製備及儲存
|
|
CA3195300A1
(en)
*
|
2020-10-16 |
2022-04-21 |
President And Fellows Of Harvard College |
Ww-domain-activated extracellular vesicles targeting hiv
|
|
US20230391834A1
(en)
*
|
2020-10-16 |
2023-12-07 |
President And Fellows Of Harvard College |
Ww-domain-activated extracellular vesicles targeting coronaviruses
|
|
WO2022081987A1
(en)
*
|
2020-10-16 |
2022-04-21 |
President And Fellows Of Harvard College |
Ww-domain-activated extracellular vesicles
|
|
AU2021363536A1
(en)
|
2020-10-20 |
2023-02-23 |
F. Hoffmann-La Roche Ag |
Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors
|
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
|
US12351643B2
(en)
|
2020-11-04 |
2025-07-08 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
|
TWI888665B
(zh)
|
2020-11-04 |
2025-07-01 |
美商建南德克公司 |
抗cd20/抗cd3雙特異性抗體之皮下給藥
|
|
CA3196191A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
KR20230104220A
(ko)
|
2020-11-05 |
2023-07-07 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
Egfr 항원을 표적화하는 조작된 t 세포 수용체 및 사용 방법
|
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
JP2023551645A
(ja)
|
2020-11-10 |
2023-12-12 |
イモデュロン セラピューティクス リミテッド |
がん治療における使用のためのマイコバクテリウム
|
|
KR20230107260A
(ko)
|
2020-11-12 |
2023-07-14 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
Sars-cov-2 스파이크 단백질의 수용체-결합 도메인에 접합되거나 융합된 항체, 및 백신 목적을 위한 이의 용도
|
|
AU2021377699A1
(en)
|
2020-11-13 |
2023-06-15 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
|
WO2022101463A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
|
|
WO2022119830A1
(en)
|
2020-12-02 |
2022-06-09 |
Genentech, Inc. |
Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
|
|
CA3204091A1
(en)
|
2020-12-08 |
2022-06-16 |
Infinity Pharmaceuticals, Inc. |
Eganelisib for use in the treatment of pd-l1 negative cancer
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
EP4055055B1
(en)
|
2020-12-18 |
2023-11-22 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
CA3205538A1
(en)
|
2021-01-19 |
2022-07-28 |
Han XIAO |
Bone-specific delivery of polypeptides
|
|
US20240384350A1
(en)
|
2021-01-29 |
2024-11-21 |
Board Of Regents, The University Of Texas System |
Methods of treating cancer with kinase inhibitors
|
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
|
|
US20240300927A1
(en)
|
2021-02-03 |
2024-09-12 |
Genentech, Inc. |
Amides as cbl-b inhibitors
|
|
AR124800A1
(es)
|
2021-02-03 |
2023-05-03 |
Genentech Inc |
Lactamas como inhibidores cbl-b
|
|
AU2022227686A1
(en)
|
2021-02-25 |
2023-07-27 |
Lyell Immunopharma, Inc. |
Ror1 targeting chimeric antigen receptor
|
|
PH12023552345A1
(en)
|
2021-03-02 |
2024-04-22 |
Glaxosmithkline Ip Dev Ltd |
Substituted pyridines as dnmt1 inhibitors
|
|
WO2022195551A1
(en)
|
2021-03-18 |
2022-09-22 |
Novartis Ag |
Biomarkers for cancer and methods of use thereof
|
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
|
WO2022208353A1
(en)
|
2021-03-31 |
2022-10-06 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins and combinations thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
WO2022216979A1
(en)
|
2021-04-08 |
2022-10-13 |
Board Of Regents, The University Of Texas System |
Compounds and methods for theranostic targeting of parp activity
|
|
KR20230167407A
(ko)
|
2021-04-08 |
2023-12-08 |
누릭스 테라퓨틱스 인코포레이티드 |
Cbl-b 억제제 화합물을 이용한 조합 요법
|
|
KR20240004462A
(ko)
|
2021-04-08 |
2024-01-11 |
마렝고 테라퓨틱스, 인크. |
Tcr에 결합하는 다기능성 분자 및 이의 용도
|
|
US20240239895A1
(en)
|
2021-04-09 |
2024-07-18 |
Genentech, Inc. |
Combination therapy with a raf inhibitor and a pd-1 axis inhibitor
|
|
EP4323356A1
(en)
|
2021-04-13 |
2024-02-21 |
Nuvalent, Inc. |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
|
CA3216880A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
WO2022232503A1
(en)
|
2021-04-30 |
2022-11-03 |
Genentech, Inc. |
Therapeutic and diagnostic methods and compositions for cancer
|
|
MX2023012408A
(es)
|
2021-04-30 |
2023-10-31 |
Hoffmann La Roche |
Dosis para tratamiento conjunto con anticuerpo biespecifico anti-cd20/anti-cd3 y conjugado anticuerpo farmaco anti-cd79b.
|
|
WO2022227015A1
(en)
|
2021-04-30 |
2022-11-03 |
Merck Sharp & Dohme Corp. |
Il4i1 inhibitors and methods of use
|
|
WO2022236134A1
(en)
|
2021-05-07 |
2022-11-10 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
AU2022277246A1
(en)
*
|
2021-05-18 |
2024-01-04 |
Hung, Mien-Chie |
Vaccine, use thereof and cancer vaccine cocktail
|
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
|
WO2022254337A1
(en)
|
2021-06-01 |
2022-12-08 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
|
CA3218590A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
|
KR20240028452A
(ko)
|
2021-07-02 |
2024-03-05 |
제넨테크, 인크. |
암을 치료하기 위한 방법 및 조성물
|
|
EP4367269A1
(en)
|
2021-07-05 |
2024-05-15 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
|
CA3225254A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
WO2023007107A1
(en)
|
2021-07-27 |
2023-02-02 |
Immodulon Therapeutics Limited |
A mycobacterium for use in cancer therapy
|
|
JP2024527049A
(ja)
|
2021-07-28 |
2024-07-19 |
ジェネンテック， インコーポレイテッド |
がんを治療するための方法及び組成物
|
|
MX2024001214A
(es)
|
2021-07-28 |
2024-02-12 |
Hoffmann La Roche |
Metodos y composiciones para tratar cancer.
|
|
US20250009877A1
(en)
|
2021-07-30 |
2025-01-09 |
Seagen Inc. |
Treatment for cancer
|
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
|
EP4380596A1
(en)
|
2021-08-04 |
2024-06-12 |
Genentech, Inc. |
Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
|
|
WO2023014922A1
(en)
|
2021-08-04 |
2023-02-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
|
US20240376100A1
(en)
|
2021-09-08 |
2024-11-14 |
Redona Therapeutics, Inc. |
Papd5 and/or papd7 inhibiting 4-oxo-1, 4-dihydroquinoline-3-carboxylic acid derivatives
|
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
|
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
|
KR20240116708A
(ko)
|
2021-10-05 |
2024-07-30 |
사이토비아 테라퓨틱스, 엘엘씨. |
자연 살해 세포 및 이의 사용 방법
|
|
WO2023057534A1
(en)
|
2021-10-06 |
2023-04-13 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
WO2023068382A2
(en)
|
2021-10-20 |
2023-04-27 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
|
US20240409934A1
(en)
|
2021-10-25 |
2024-12-12 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
|
JP2024541933A
(ja)
|
2021-11-02 |
2024-11-13 |
ファイザー・インク |
抗ｇｄｆ１５抗体を使用してミトコンドリア筋症を処置する方法
|
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
|
MX2024005722A
(es)
|
2021-11-12 |
2024-05-28 |
Novartis Ag |
Terapia de combinacion para el tratamiento del cancer de pulmon.
|
|
KR20240103030A
(ko)
|
2021-11-17 |
2024-07-03 |
인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 |
범용 사르베코바이러스 백신
|
|
US12275745B2
(en)
|
2021-11-24 |
2025-04-15 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
US12110276B2
(en)
|
2021-11-24 |
2024-10-08 |
Genentech, Inc. |
Pyrazolo compounds and methods of use thereof
|
|
IL313439A
(en)
|
2021-12-16 |
2024-08-01 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
WO2023129438A1
(en)
|
2021-12-28 |
2023-07-06 |
Wisconsin Alumni Research Foundation |
Hydrogel compositions for use for depletion of tumor associated macrophages
|
|
WO2023154905A1
(en)
|
2022-02-14 |
2023-08-17 |
Gilead Sciences, Inc. |
Antiviral pyrazolopyridinone compounds
|
|
WO2023154799A1
(en)
|
2022-02-14 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination immunotherapy for treating cancer
|
|
CN119487067A
(zh)
|
2022-04-01 |
2025-02-18 |
基因泰克公司 |
用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
|
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
IL316738A
(en)
|
2022-05-11 |
2024-12-01 |
Genentech Inc |
Dosage for treatment with anti-FCRH5/anti-CD3 bispecific antibodies
|
|
IL316628A
(en)
|
2022-05-12 |
2024-12-01 |
Genmab As |
Binding agents capable of binding to CD27 in combination therapy
|
|
AR129423A1
(es)
|
2022-05-27 |
2024-08-21 |
Viiv Healthcare Co |
Compuestos útiles en la terapia contra el hiv
|
|
JP2025523387A
(ja)
|
2022-06-07 |
2025-07-23 |
ジェネンテック， インコーポレイテッド |
抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
|
|
WO2023242351A1
(en)
|
2022-06-16 |
2023-12-21 |
Lamkap Bio Beta Ag |
Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
|
|
JP2025521543A
(ja)
|
2022-06-22 |
2025-07-10 |
ジュノー セラピューティクス インコーポレイテッド |
Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
EP4554978A1
(en)
|
2022-07-13 |
2025-05-21 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
TW202413433A
(zh)
|
2022-07-19 |
2024-04-01 |
美商建南德克公司 |
用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
|
|
WO2024028794A1
(en)
|
2022-08-02 |
2024-02-08 |
Temple Therapeutics BV |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
|
EP4565262A2
(en)
|
2022-08-05 |
2025-06-11 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
|
EP4581366A1
(en)
|
2022-09-01 |
2025-07-09 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
WO2024052356A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|
|
EP4599089A1
(en)
|
2022-10-05 |
2025-08-13 |
Genentech, Inc. |
Methods and compositions for classifying and treating bladder cancer
|
|
EP4599088A1
(en)
|
2022-10-05 |
2025-08-13 |
Genentech, Inc. |
Methods and compositions for classifying and treating lung cancer
|
|
TW202426503A
(zh)
|
2022-10-19 |
2024-07-01 |
日商安斯泰來製藥股份有限公司 |
癌症治療中與ｐｄ－１訊息抑制劑組合之抗ｃｌｄｎ４－抗ｃｄ１３７雙特異性抗體的用途
|
|
EP4609201A1
(en)
|
2022-10-25 |
2025-09-03 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
|
WO2024115725A1
(en)
|
2022-12-01 |
2024-06-06 |
BioNTech SE |
Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
|
|
EP4633664A2
(en)
|
2022-12-13 |
2025-10-22 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
|
AU2023393653A1
(en)
|
2022-12-14 |
2025-05-22 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|
|
TW202440154A
(zh)
|
2022-12-20 |
2024-10-16 |
美商建南德克公司 |
用ｐｄ－１軸結合拮抗劑及ｒｎａ疫苗治療胰臟癌之方法
|
|
WO2024163477A1
(en)
|
2023-01-31 |
2024-08-08 |
University Of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
WO2024197157A1
(en)
|
2023-03-21 |
2024-09-26 |
Biograph 55, Inc. |
Cd19/cd38 multispecific antibodies
|
|
TW202502311A
(zh)
|
2023-03-29 |
2025-01-16 |
美商默沙東有限責任公司 |
Il4i1抑制劑及其使用方法
|
|
WO2024209072A1
(en)
|
2023-04-06 |
2024-10-10 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 for treating cancer
|
|
WO2024213767A1
(en)
|
2023-04-14 |
2024-10-17 |
Institut National de la Santé et de la Recherche Médicale |
Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
|
|
AU2024265613A1
(en)
|
2023-05-04 |
2025-09-25 |
Novasenta, Inc. |
Anti-cd161 antibodies and methods of use thereof
|
|
WO2024233341A1
(en)
|
2023-05-05 |
2024-11-14 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024233646A1
(en)
|
2023-05-10 |
2024-11-14 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
AR132668A1
(es)
|
2023-05-12 |
2025-07-16 |
Genmab As |
Anticuerpos capaces de unirse a ox40, variantes de los mismos y usos de los mismos
|
|
WO2024261302A1
(en)
|
2023-06-22 |
2024-12-26 |
Institut National de la Santé et de la Recherche Médicale |
Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
|
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2025003193A1
(en)
|
2023-06-26 |
2025-01-02 |
Institut National de la Santé et de la Recherche Médicale |
Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
|
|
WO2025012417A1
(en)
|
2023-07-13 |
2025-01-16 |
Institut National de la Santé et de la Recherche Médicale |
Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
|
|
WO2025024257A1
(en)
|
2023-07-21 |
2025-01-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2025021201A1
(en)
*
|
2023-07-26 |
2025-01-30 |
BRL Medicine Inc. |
Method and composition for treating diseases
|
|
WO2025042742A1
(en)
|
2023-08-18 |
2025-02-27 |
Bristol-Myers Squibb Company |
Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
|
|
WO2025049277A1
(en)
|
2023-08-25 |
2025-03-06 |
Genentech, Inc. |
Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
|
|
WO2025050009A2
(en)
|
2023-09-01 |
2025-03-06 |
Children's Hospital Medical Center |
Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025064744A1
(en)
|
2023-09-22 |
2025-03-27 |
Tyra Biosciences, Inc. |
Tyra-300 (5-[(1r)-1-(3,5-dichloro-4-pyridyl)ethoxy]-3-[6-(2-methylsulfonyl-2,6-diazaspiro[3.3]heptan-6-yl)-3-pyridyl]-1h-indazole ) in combination with a pd-1 or pd-l1 antagonist for use in the treatment of cancer
|
|
WO2025085404A1
(en)
|
2023-10-16 |
2025-04-24 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treating lung cancer
|
|
WO2025085781A1
(en)
|
2023-10-19 |
2025-04-24 |
Genentech, Inc. |
Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers
|
|
WO2025114541A1
(en)
|
2023-11-30 |
2025-06-05 |
Genmab A/S |
Antibodies capable of binding to ox40 in combination therapy
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025155607A1
(en)
|
2024-01-16 |
2025-07-24 |
Genentech, Inc. |
Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine
|
|
WO2025174933A1
(en)
|
2024-02-14 |
2025-08-21 |
Genentech, Inc. |
Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel
|
|
WO2025210175A1
(en)
|
2024-04-04 |
2025-10-09 |
Centre National De La Recherche Scientifique |
Mutant csf-1r extracellular domain fusion molecules and therapeutic uses thereof
|
|
WO2025248505A1
(en)
|
2024-05-31 |
2025-12-04 |
Wayne State University |
Methods for treating endometrial and ovarian hyperproliferative disorders
|